AzTrials
AzTrials

Buccal Defect At Implant SitesEarly Phase 1NCT04873830

Volumetric Assessment of Volume Stable Collagen Matrix in Soft Tissue Ridge Augmentation

A Early Phase 1 study testing volume stable collagen matrix placement and connective tissue grafting in people with Buccal Defect At Implant Sites, run by Ain Shams University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This proposal suggests the use of a collagen scaffold as a core material for GBR in the case of a missing tooth between two existing teeth, in situations where there is sufficient bone to place an implant but a horizontal defect is present in the ridge. Read more about this study

Who is it for?
Ages 20 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Buccal Defect At Implant Sites
What is being tested?
volume stable collagen matrix placement and connective tissue grafting
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteEgypt
Study dates
22 Nov 2021to 27 May 2023
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adult patients in a healthy systemic condition.
  • Both genders with age ranging from 20 to 50 years old.
  • Patients should have single missing tooth in anterior or premolar area.
  • Seibert Class I ridge defect.
  • Sufficient bone height and width that doesn't necessitate bone grafting or any other ridge augmentation protocols.
  • Healing period of 3 months after extraction prior to surgical procedures.
  • Patients should approve to deliver a signature to a written consent after study nature explanation.

Who cannot join

  • Patients with any smoking habits.
  • Pregnant females, decisional impaired individuals, Prisoners and handicapped patients.
  • Patients having poor oral hygiene or not wanting to carry out oral hygiene measures.
  • Patients with infections either periodontally or periapically.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ain Shams Dental School

    Cairo, 11516

Other trials in Egypt

About this study

Official title: Volumetric Assessment of Volume Stable Collagen Matrix in Soft Tissue Ridge Augmentation At Maxillary Single Implant Site

This proposal suggests the use of a collagen scaffold as a core material for GBR in the case of a missing tooth between two existing teeth, in situations where there is sufficient bone to place an implant but a horizontal defect is present in the ridge.

The tested question is whether a thick, reinforced, resorbable collagen scaffold can provide a stable basis for restoring the lost volume of a deficient ridge. As a secondary aim, a positive result could present an option to replace the connective tissue interpositional graft procedure.

Read the detailed description
  • Surgical procedure and clinical measurements:

Pre-surgical phase:

  1. Full Conventional non-surgical periodontal therapy involving supra, sub gingival scaling and root planning will be performed
  2. Oral hygiene instructions will be repeated until patients had achieved a proper degree of oral hygiene where plaque index (PI) ≤ 1.
  3. Four weeks later, patients will be re-evaluated in order to confirm the efficacy of cause related therapy phase.
  4. Clinical parameters and CBCT will be recorded prior to surgery.
  5. Full arch impressions will be recorded with high viscosity impression material. Baseline casts will be made to be used as a reference for volumetric measurements.
  • Surgical protocol:
  • Patients will undertake implant surgery under local anesthesia for the missing tooth using mid crestal incision at the edentulous area and sulcular incisions at the neighboring mesial and distal teeth.
  • A combined full / partial thickness flap will be made followed by implant placement and healing screw is connected to the implant.
  • For group 1 VCMX will be utilized to graft the buccal defect and primary closure will be achieved using simple interrupted sutures.
  • For group 2 CTG will be utilized to graft the buccal defect and primary closure will be achieved using simple interrupted sutures.
  • Postoperative medications will include (Augmentin 1g twice/day, Flagel 500 mg twice daily and 2 weeks of antiseptic mouth wash ).(Deeb et al , 2015)
  • Patients will be given post-operative instruction and sutures will be removed after 2 weeks.
  • The final abutment will be secured to the implant within 12 weeks after gingival healing for definitive crown placement.

Postoperative surgical evaluation and assessment:

  • The follow up period will include oral examination, plaque removal when necessary, at the surgical site.
  • Clinical parameters will be measured, impressions redone, and models will be casted 3, 6 and 9 months postoperatively for both groups.
  • Radiographic examination using CBCT will be done at 9 months follow up.

Methods of evaluation:

  1. Clinical Measurements:
  • Probing depth (Glavind \& Loe, 1967).
  • Plaque index (O'leary T, 1972).
  • Bleeding index (Newbrun, 1996)
  • Volumetric changes at the augmented implant site digitally through scanning model casts. To assess the volumetric differences between the baseline, 3, 6 and 9 months postoperatively and all the cast models will be transferred to digital replica using an optical scanner. Digital replicas will be produced resembling various time intervals during treatment. Superimposing the different replicas of each case utilizing the best fit algorithm by using reference points from the tooth surfaces. The implant site region will be delineated by the mucogingival line, the mesial and distal papillary midline and the alveolar crest. Thus, any.alterations in volume between the digitized superimposed replicas could be recorded. (Akcali et al., 2015)
  • Pink esthetic score. Pink esthetic score will be recorded for five variables: "mesial papilla, distal papilla, curvature of the facial mucosa, level of the facial mucosa, and root convexity/soft tissue color and texture at the facial aspect of the implant site". A score of 2, 1, or 0 will be assigned to all five PES parameters. The two papillary scores (mesial and distal) will be assessed for the complete presence (score 2), incomplete presence (score 1) or absence (score0) of papillary tissue. The curvature of the facial soft tissue line, also defined as the line of emergence of the implant restoration from the soft tissues, will be evaluated as being identical (score 2 ), slightly different (score 1), or markedly different (score 0) compared to the natural control tooth and thus, provided a natural symmetrical or disharmonious appearance and in comparison to the contralateral tooth in terms of an identical vertical level (score 2), a slight (<1 mm) discrepancy (score 1), or a major (>1 mm) discrepancy (score 0). Finally, the combined three additional specific soft tissue parameters as one variable: the presence, partial presence, or absence of a convex profile (in analogy to a root eminence) on the facial aspect, as-well-as-the-related-mucosal-color-and-surface texture. To achieve a score of 2 for this-combination-variable, all-three-parameters-were more-or-less-identical-compared-to-the-control-tooth. A value of 1 will be given if two criteria are fulfilled, whereas a score of 0 will be given if none or only one parameter matches the control site. (Tettamanti et al, 2014)
  • Visual analogue scale to measure postoperative pain. Pain.score.reported.by.the.patient. directly.through.Visual.Analogue.Scale.score (from 0 to 10. 0: no pain, 1: minimal pain, 5: moderate pain, 10: severe pain) VAS will be recorded after 2 weeks (Yıldırım et al., 2017)
  • The OHIP (OHIP-14 questionnaire) Will be used to assess limitation of function , pain , discomfort, social , psychological ,physical disability and general satisfaction. The OHIP-14 utilizes a scale with five categories (1 = never, 2 = hardly ever, 3 = occasionally, 4 = fairly often, and 5 = very often).A lower score in any of the five categories indicates higher satisfaction. (Al-zubeidi et al, 2011)
  • Soft tissue thickness will be measured at baseline and 9 months postoperatively using.an.anesthetic.needle.with.a.rubber.stopper to pierce the gingiva horizontally and perpendicular to the long axis of the tooth till bone contact 2mm coronal to the MGJ and in the mid distance mesiodistally
  • The part of the instrument penetrating into soft tissue will be measured in mm. (Cairo et al 2017)
  1. Radiographic Examination:
  • Cone Beam Computed Tomography (CBCT) will be taken at baseline before implant placement and 9 months later to measure soft tissue thickness.

Statistical analysis:

The collected data will be revised, coded, tabulated and introduced to a PC using Statistical package for Social Science (SPSS 15.0 for windows; SPSS Inc, Chicago, IL, 2001). Data will be presented and suitable analysis will be done according to the type of data obtained for each parameter.

Being tested
volume stable collagen matrix placement, connective tissue grafting
Keywords
siebert, dental implant, volume stable collagen matrix, connective tissue

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • volume stable collagen matrix placementBiological

    volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement

  • connective tissue graftingProcedure or surgery

    connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement

Study groups in NCT04873830
Study groupRoleWhat they receive
Group I (VCMX)Experimentalincludes 10 patients where implant placement will be performed followed by volume stable collagen matrix placement to augment the buccal defect.
Receives: Biological: volume stable collagen matrix placement
Group II (control)ExperimentalWill include 10 patients where implant placement will be performed followed by connective tissue grafting to augment the buccal defect.
Receives: Procedure: connective tissue grafting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. volumetric changes of soft tissue at implant sites with siebert class I

    Is to evaluate the volumetric changes of soft tissues at implant sites with Siebert class I ridge defect after augmentation with volume stable collagen matrix in comparison with connective tissue grafting

    Measured: 9 months

Secondary outcomes (2)
  1. esthetic outcome

    Pink esthetic score will be recorded for five variables: "mesial papilla, distal papilla, curvature of the facial mucosa, level of the facial mucosa, and root convexity/soft tissue color and texture at the facial aspect of the implant site". A score of 2, 1, or 0 will be assigned to all five PES parameters.

    Measured: 9 months

  2. patient satisfaction

    using a satisfaction questionnaire

    Measured: 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2021
  2. Study start22 Nov 2021
  3. Primary completion29 Mar 2023
  4. Study completion27 May 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04873830
Sponsor's protocol ID
ainshamsUni
Status last verified
Nov 2024
First submitted
4 May 2021
Last updated
25 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing volume stable collagen matrix placement and connective tissue grafting in people with Buccal Defect At Implant Sites, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

volumetric changes of soft tissue at implant sites with siebert class I (time frame: 9 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2024; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in